Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1995 Aug;33(8):2058–2063. doi: 10.1128/jcm.33.8.2058-2063.1995

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.

C E Greer 1, C M Wheeler 1, M B Ladner 1, K Beutner 1, M Y Coyne 1, H Liang 1, A Langenberg 1, T S Yen 1, R Ralston 1
PMCID: PMC228335  PMID: 7559948

Abstract

Thirty-nine patients with condylomas (12 women and 27 men) attending a dermatology clinic were tested for genital human papillomavirus (HPV) DNA and for seroprevalence to HPV type 6 (HPV6) L1 virus-like particles. The L1 consensus PCR system (with primers MY09 and MY11) was used to determine the presence and types of HPV in sample specimens. All 37 (100%) patients with sufficient DNA specimens were positive for HPV DNA, and 35 (94%) had HPV6 DNA detected at the wart site. Three patients (8%) had HPV11 detected at the wart site, and one patient had both HPV6 and -11 detected at the wart site. Thirteen additional HPV types were detected among the patients; the most frequent were HPV54 (8%) and HPV58 (8%). Baculovirus-expressed HPV6 L1 virus-like particles were used in enzyme-linked immunosorbent assays to determine seroprevalence among the patients with warts. Seronegativity was defined by a control group of 21 women who were consistently PCR negative for HPV DNA. Seroprevalence was also determined for reference groups that included cytologically normal women who had detectable DNA from either HPV6 or HPV16 and women with HPV16-associated cervical intraepithelial neoplasia. Among the asymptomatic women with HPV6, only 2 of 9 (22%) were seropositive, compared with 12 of 12 (100%) female patients with warts. A similar trend in increased HPV6 seropositivity with increased grade of disease was found with the HPV16 DNA-positive women, whose seroprevalence increased from 1 in 11 (9%) in cytologically normal women to 6 in 15 (40%) among women with cervical intraepithelial neoplasia 1 or 3. However, only 4 of 25 (16%) male patients were seropositive.(ABSTRACT TRUNCATED AT 250 WORDS)

Full Text

The Full Text of this article is available as a PDF (387.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ansar Ahmed S., Penhale W. J., Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol. 1985 Dec;121(3):531–551. [PMC free article] [PubMed] [Google Scholar]
  2. Bauer H. M., Ting Y., Greer C. E., Chambers J. C., Tashiro C. J., Chimera J., Reingold A., Manos M. M. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991 Jan 23;265(4):472–477. [PubMed] [Google Scholar]
  3. Becker T. M., Wheeler C. M., McGough N. S., Parmenter C. A., Jordan S. W., Stidley C. A., McPherson R. S., Dorin M. H. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. JAMA. 1994 Apr 20;271(15):1181–1188. [PubMed] [Google Scholar]
  4. Bernard H. U., Chan S. Y., Manos M. M., Ong C. K., Villa L. L., Delius H., Peyton C. L., Bauer H. M., Wheeler C. M. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis. 1994 Nov;170(5):1077–1085. doi: 10.1093/infdis/170.5.1077. [DOI] [PubMed] [Google Scholar]
  5. Bonnez W., Da Rin C., Rose R. C., Reichman R. C. Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol. 1991 Jun;72(Pt 6):1343–1347. doi: 10.1099/0022-1317-72-6-1343. [DOI] [PubMed] [Google Scholar]
  6. Bonnez W., Da Rin C., Rose R. C., Tyring S. K., Reichman R. C. Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response. J Med Virol. 1993 Apr;39(4):340–344. doi: 10.1002/jmv.1890390414. [DOI] [PubMed] [Google Scholar]
  7. Bonnez W., Kashima H. K., Leventhal B., Mounts P., Rose R. C., Reichman R. C., Shah K. V. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology. 1992 May;188(1):384–387. doi: 10.1016/0042-6822(92)90770-p. [DOI] [PubMed] [Google Scholar]
  8. Carter J. J., Hagensee M. B., Lee S. K., McKnight B., Koutsky L. A., Galloway D. A. Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology. 1994 Mar;199(2):284–291. doi: 10.1006/viro.1994.1126. [DOI] [PubMed] [Google Scholar]
  9. Carter J. J., Hagensee M., Taflin M. C., Lee S. K., Koutsky L. A., Galloway D. A. HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology. 1993 Aug;195(2):456–462. doi: 10.1006/viro.1993.1396. [DOI] [PubMed] [Google Scholar]
  10. Christensen N. D., Kreider J. W., Cladel N. M., Galloway D. A. Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins. Virology. 1990 Mar;175(1):1–9. doi: 10.1016/0042-6822(90)90180-y. [DOI] [PubMed] [Google Scholar]
  11. Christensen N. D., Kreider J. W., Shah K. V., Rando R. F. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol. 1992 May;73(Pt 5):1261–1267. doi: 10.1099/0022-1317-73-5-1261. [DOI] [PubMed] [Google Scholar]
  12. Eidinger D., Garrett T. J. Studies of the regulatory effects of the sex hormones on antibody formation and stem cell differentiation. J Exp Med. 1972 Nov 1;136(5):1098–1116. doi: 10.1084/jem.136.5.1098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol. 1975 May;15(5):1239–1247. doi: 10.1128/jvi.15.5.1239-1247.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Firzlaff J. M., Kiviat N. B., Beckmann A. M., Jenison S. A., Galloway D. A. Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology. 1988 Jun;164(2):467–477. doi: 10.1016/0042-6822(88)90561-2. [DOI] [PubMed] [Google Scholar]
  15. Ghim S. J., Jenson A. B., Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology. 1992 Sep;190(1):548–552. doi: 10.1016/0042-6822(92)91251-o. [DOI] [PubMed] [Google Scholar]
  16. Gravitt P. E., Manos M. M. Polymerase chain reaction-based methods for the detection of human papillomavirus DNA. IARC Sci Publ. 1992;(119):121–133. [PubMed] [Google Scholar]
  17. Grossman C. J. Interactions between the gonadal steroids and the immune system. Science. 1985 Jan 18;227(4684):257–261. doi: 10.1126/science.3871252. [DOI] [PubMed] [Google Scholar]
  18. Hildesheim A., Schiffman M. H., Gravitt P. E., Glass A. G., Greer C. E., Zhang T., Scott D. R., Rush B. B., Lawler P., Sherman M. E. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994 Feb;169(2):235–240. doi: 10.1093/infdis/169.2.235. [DOI] [PubMed] [Google Scholar]
  19. Hjorth R., Moreno-Lopez L. Purification of bovine papilloma virus by gel filtration on Sephacryl S-1000 superfine. J Virol Methods. 1982 Nov;5(3-4):151–158. doi: 10.1016/0166-0934(82)90004-0. [DOI] [PubMed] [Google Scholar]
  20. Jenison S. A., Yu X. P., Valentine J. M., Galloway D. A. Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope. J Virol. 1989 Feb;63(2):809–818. doi: 10.1128/jvi.63.2.809-818.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D. R., Schiller J. T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994 Apr 6;86(7):494–499. doi: 10.1093/jnci/86.7.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kreider J. W., Howett M. K., Leure-Dupree A. E., Zaino R. J., Weber J. A. Laboratory production in vivo of infectious human papillomavirus type 11. J Virol. 1987 Feb;61(2):590–593. doi: 10.1128/jvi.61.2.590-593.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Langenberg A., Cone R. W., McDougall J., Kiviat N., Corey L. Dual infection with human papillomavirus in a population with overt genital condylomas. J Am Acad Dermatol. 1993 Mar;28(3):434–442. doi: 10.1016/0190-9622(93)70064-z. [DOI] [PubMed] [Google Scholar]
  24. London W. T., Drew J. S. Sex differences in response to hepatitis B infection among patients receiving chronic dialysis treatment. Proc Natl Acad Sci U S A. 1977 Jun;74(6):2561–2563. doi: 10.1073/pnas.74.6.2561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Manos M. M., Waldman J., Zhang T. Y., Greer C. E., Eichinger G., Schiffman M. H., Wheeler C. M. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis. 1994 Nov;170(5):1096–1099. doi: 10.1093/infdis/170.5.1096. [DOI] [PubMed] [Google Scholar]
  26. Michaels R. M., Rogers K. D. A sex difference in immunologic responsiveness. Pediatrics. 1971 Jan;47(1):120–123. [PubMed] [Google Scholar]
  27. Munemitsu S., Innis M. A., Clark R., McCormick F., Ullrich A., Polakis P. Molecular cloning and expression of a G25K cDNA, the human homolog of the yeast cell cycle gene CDC42. Mol Cell Biol. 1990 Nov;10(11):5977–5982. doi: 10.1128/mcb.10.11.5977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Paty D. W., Furesz J., Boucher D. W., Rand C. G., Stiller C. R. Measles antibodies as related to HL-A types in multiple sclerosis. Neurology. 1976 Jul;26(7):651–655. doi: 10.1212/wnl.26.7.651. [DOI] [PubMed] [Google Scholar]
  29. Pfister H., zur Hausen H. Seroepidemiological studies of human papilloma virus (HPV-1) infections. Int J Cancer. 1978 Feb 15;21(2):161–165. doi: 10.1002/ijc.2910210206. [DOI] [PubMed] [Google Scholar]
  30. Rhodes K., Scott A., Markham R. L., Monk-Jones M. E. Immunological sex differences. A study of patients with rheumatoid arthritis, their relatives, and controls. Ann Rheum Dis. 1969 Mar;28(2):104–120. doi: 10.1136/ard.28.2.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rose R. C., Bonnez W., Da Rin C., McCance D. J., Reichman R. C. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol. 1994 Sep;75(Pt 9):2445–2449. doi: 10.1099/0022-1317-75-9-2445. [DOI] [PubMed] [Google Scholar]
  32. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993 Apr;67(4):1936–1944. doi: 10.1128/jvi.67.4.1936-1944.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schiffman M. H., Bauer H. M., Hoover R. N., Glass A. G., Cadell D. M., Rush B. B., Scott D. R., Sherman M. E., Kurman R. J., Wacholder S. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993 Jun 16;85(12):958–964. doi: 10.1093/jnci/85.12.958. [DOI] [PubMed] [Google Scholar]
  34. Schuurs A. H., Verheul H. A. Effects of gender and sex steroids on the immune response. J Steroid Biochem. 1990 Feb;35(2):157–172. doi: 10.1016/0022-4731(90)90270-3. [DOI] [PubMed] [Google Scholar]
  35. Schwarz E., Dürst M., Demankowski C., Lattermann O., Zech R., Wolfsperger E., Suhai S., zur Hausen H. DNA sequence and genome organization of genital human papillomavirus type 6b. EMBO J. 1983;2(12):2341–2348. doi: 10.1002/j.1460-2075.1983.tb01744.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Steele J. C., Gallimore P. H. Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1. Virology. 1990 Feb;174(2):388–398. doi: 10.1016/0042-6822(90)90092-6. [DOI] [PubMed] [Google Scholar]
  37. Straus S. E., Savarese B., Tigges M., Freifeld A. G., Krause P. R., Margolis D. M., Meier J. L., Paar D. P., Adair S. F., Dina D. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis. 1993 May;167(5):1045–1052. doi: 10.1093/infdis/167.5.1045. [DOI] [PubMed] [Google Scholar]
  38. Sugase M., Moriyama S., Matsukura T. Human papillomavirus in exophytic condylomatous lesions on different female genital regions. J Med Virol. 1991 May;34(1):1–6. doi: 10.1002/jmv.1890340102. [DOI] [PubMed] [Google Scholar]
  39. Tachezy R., Hamsikova E., Valvoda J., Van Ranst M., Betka J., Burk R. D., Vonka V. Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: correlation between Southern blot hybridization, polymerase chain reaction, and serology. J Med Virol. 1994 Jan;42(1):52–59. doi: 10.1002/jmv.1890420111. [DOI] [PubMed] [Google Scholar]
  40. Viac J., Chomel J. J., Chardonnet Y., Aymard M. Incidence of antibodies to human papillomavirus type 1 in patients with cutaneous and mucosal papillomas. J Med Virol. 1990 Sep;32(1):18–21. doi: 10.1002/jmv.1890320104. [DOI] [PubMed] [Google Scholar]
  41. Wheeler C. M., Parmenter C. A., Hunt W. C., Becker T. M., Greer C. E., Hildesheim A., Manos M. M. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis. 1993 Sep-Oct;20(5):286–289. doi: 10.1097/00007435-199309000-00009. [DOI] [PubMed] [Google Scholar]
  42. Yaegashi N., Jenison S. A., Batra M., Galloway D. A. Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11. J Virol. 1992 Apr;66(4):2008–2019. doi: 10.1128/jvi.66.4.2008-2019.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Yaegashi N., Jenison S. A., Valentine J. M., Dunn M., Taichman L. B., Baker D. A., Galloway D. A. Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol. 1991 Mar;65(3):1578–1583. doi: 10.1128/jvi.65.3.1578-1583.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. de Villiers E. M. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol. 1994;186:1–12. doi: 10.1007/978-3-642-78487-3_1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES